Downloads: 4 | Views: 43 | Weekly Hits: ⮙4 | Monthly Hits: ⮙4

Research Proposals or Synopsis | Ayurveda | India | Volume 14 Issue 1, January 2025 | Popularity: 5.7 / 10

Rate This Article!      

An Open Label Comparative Clinical Study on Virechana Karma and Patra Pinda Sweda followed by Vishwadi Dwadashanga Kwatha in the Management of Mamsagata Vata w.s.r to Fibromyalgia

Dr. Govind Narayan, Ashish Mehta

Abstract: Background: Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, and tenderness, often accompanied by sleep disturbances, cognitive dysfunction, and mood disorders. Conventional treatments primarily focus on symptom management, often yielding suboptimal outcomes. Ayurveda correlates fibromyalgia with Mamsagata Vata, involving Vata dosha vitiation in muscular tissues (Mamsa dhatu), causing pain, stiffness, and functional impairment. Ayurveda management aims to restore dosha balance and enhance tissue health through holistic therapies. Virechana Karma (therapeutic purgation) detoxifies the body, targeting Pitta and Vata dosha, and reduces inflammation. Patra Pinda Sweda (herbal leaf bolus fomentation) alleviates pain and stiffness by improving circulation and relaxing muscles. Vishwadi Dwadashanga Kwatha, a herbal decoction, provides analgesic, anti-inflammatory, and Vata-pacifying benefits, supporting long-term relief from musculoskeletal disorders. This study aims to evaluate the comparative effectiveness of Virechana Karma and Patra Pinda Sweda followed by Vishwadi Dwadashanga Kwatha in managing Mamsagata Vata, with a focus on fibromyalgia. Integrating purification, external therapies, and internal medication, the research seeks to provide an evidence-based, holistic approach to managing this complex condition. Objective: The Primary aim is To compare the effect of Virechana Karma and Patra Pinda Sweda Followed by Viswadi Dwadashanga Kwatha in the management of Mamsagata Vata with special reference to Fibromyalgia. Methods: This ongoing study is an open-label randomized comparative interventional trial, with a sample size of 78 both in the trial and standard control group (including dropouts, 10%). Participants in the trial group will receive Virechana Karma. Followed by Viswadi Dwadashanga Kwatha 20 GM BD (Morning and evening before meal) with Luke warm water for a period of fifteen days. The participants in the control group will receive Patra Pinda Sweda followed by Viswadi Dwadashanga Kwatha 20 GM BD (Morning and evening before meal) with Luke warm water for 15days. Outcome Measures: The primary outcome will include the mean change & improvement present in Mamsagata Vata symptoms of registered patients, improvement and change present symptoms in fibromyalgia. The secondary outcomes will include the Changes in FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQ). Ethics: Ethics approval was taken from the Institutional Ethics Committee following which recruitment will be commenced in January 2025.

Keywords: Mamsagata vata, Fibromyalgia, Vishwadi dwadashanga kwatha, Patra pinda sweda, virechana karma

Edition: Volume 14 Issue 1, January 2025

Pages: 72 - 80

DOI: https://www.doi.org/10.21275/SR241230133900

Make Sure to Disable the Pop-Up Blocker of Web Browser

Click to Cite this Article

Similar Articles